Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — H.C. Wainwright Global Investment Conference 2021
20 slides from Stablecoin Development's conference presentation, September 2021
Slide 1: Investor Presentation
Investor Presentation H.C. Wainwright Global Investment Conference September 13-15, 2021 NYSE American: NBY www.Novabay.com www.Avenova.com www.Cellerx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: NovaBay Overview
NovaBay Overview • Established Avenova® as the No. 1 antimicrobial lid and lash spray in the U.S. dry eye market • Multi-pronged commercial distribution strategy • Available direct-to-consumer without a prescription • Online channels like Amazon.com, Walmart.com, CVS.com, and Avenova.com • CVS Pharm
Slide 4: Recent Developments
Recent Developments • Partnership with ImprimisRx® to promote Prescription Avenova • A leading U.S. ophthalmology-focused pharmaceutical business • Proven success in commercializing high-quality ophthalmic products • Customer base of thousands of eye care specialists • Provides surgical dilation age
Slide 5: Investment Highlights
Investment Highlights • Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits • Avenova is the only commercial hypochlorous acid (HOCI) spray clinically proven to treat the underlying cause rather than the sym
Slide 6: Patented HOCI Formulation is a Platform Technology
Patented HOCI Formulation is a Platform Technology AVENOVA AND CELLERX ARE ALL FORMULATED WITH NOVABAY’S PURE HOCI, WHICH IS FDA 510(K) CLEARED Natural molecule is part of the body’s innate immune system • Effective against all types of pathogens, including a wide variety of viruses such as coronavi
Slide 7: Avenova Market Opportunity
Avenova Market Opportunity U.S. POPULATION WITH EYE BACTERIA CONCERNS Bacterial Dry Eye is the Most Common Form • Bacterial dry eye (meibomian gland dysfunction and blepharitis) represents 86% of dry eye patients • Aqueous deficient dry eye, treated by Restasis and 11 Million Xiidra, represent ONLY
Slide 8: Avenova Advantages
Avenova Advantages • Clinical study confirms Avenova’s ability to reduce bacteria on ocular surface by >90%, not merely treat the symptoms • Kills >20 microorganisms connected to common eye infections within seconds; effective against a range of pathogens including Staphylococcus • Stable formulatio
Slide 9: Direct-to-Consumer Strategy
Direct-to-Consumer Strategy • Accounts for more than 70% of Avenova revenue • Provides easy access to Avenova without a prescription or leaving home • Helps to offset the impact of high-deductible healthcare plans avenova.com • Provides NovaBay with stable gross-to-net pricing • Expanding the custom
Slide 10: Refreshed Consumer Lifestyle Branding
Refreshed Consumer Lifestyle Branding @avenovaeyecare 10
Slide 11: Avenova Prescription Sales Channels
Avenova Prescription Sales Channels • Rx Sales/Prescription Channel • Partnership with ImprimisRx to promote prescription Avenova to nationwide network of thousands of ophthalmologists and Retail optometrists Pharmacies • Avenova is available in virtually all U.S. retail pharmacies • Specialty Pharm
Slide 12: KOL Advisory Boards Provide Third-Party Credibility
KOL Advisory Boards Provide Third-Party Credibility • Advisory boards of industry leaders comprised of 10 ophthalmologists and 10 optometrists • Creates “doctor recommended” halo effect • Provide valuable insight into doctor perspectives on Avenova and the market • Assist in developing strategic mes
Slide 13: CelleRx Clinical Reset
CelleRx Clinical Reset INPROCESS Launched 4Q’20 Direct-to-Consumer in the Beauty Market Clinical Reset is a Gentle, Calming and Soothing Daily Facial Mist 13
Slide 14: CelleRx Clinical Reset | A New Category in Beauty Products
CelleRx Clinical Reset | A New Category in Beauty Products • FDA-cleared skincare product proven to help clean and reduce bacteria buildup on facial skin • Removes barriers to cell regeneration through gentle cleansing and biofilm disruption, without stripping the skin • Complementary to a daily bea
Slide 15: CelleRx Clinical Reset – Social Media Marketing
CelleRx Clinical Reset – Social Media Marketing INPROCESS @CELLERXSKIN SOCIAL MEDIA PRESENCE FOR BEAUTY AND SKIN MARKET DAILY POSTING AND STORIES LIFESTYLE IMAGES AND CONTENT PRESCRIPTION GRADE SKINCARE 15
Slide 16: CelleRx Clinical Reset Consumer Strategy
CelleRx Clinical Reset Consumer Strategy • Leveraging new consumer-focused messaging and NovaBay’s pharmaceutical pedigree in robust social media and print advertising campaigns marketing in the beauty industry • Debuting with a strong digital marketing presence across all digital channels allowing
Slide 17: Leadership
Leadership • Extensive knowledge of NovaBay, having joined in 2013 and serving as CEO since 2019 JUSTIN M. HALL, ESQ • Lead successful restructuring, implemented direct-to-consumer strategy and leading consumer launch of CelleRx CEO, General Counsel & Director • Extensive legal background on wide ra
Slide 18: Strategy for Growth
Strategy for Growth • Driving Avenova and CelleRx Clinical Reset sales to consumers • DTC channel presents the greatest opportunity for growth • Enhanced e-commerce, digital marketing and advertising programs, and refreshed branding • Expanded online access and new brick-and-mortar availability • Ex
Slide 19: Financial and Operating Highlights
Financial and Operating Highlights • Second quarter 2021 Avenova OTC sales of $1.3 million topped the $1 million for the 2nd consecutive quarter, with 4 consecutive quarters of record unit sales • Sales growth anticipated from refreshed digital advertising campaigns, newly launched and licensed prod
Slide 20: In Summary
In Summary • Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits • Avenova is the only commercial hypochlorous acid (HOCI) spray clinically proven to treat the underlying cause rather than the symptoms of ba
NovaBay Pharmaceuticals — H.C. Wainwright Global Investment Conference 2021 on 6ix